Related Experiment Videos
Current trends and prospects in surgical adjuvant trials
Archiv Fur Geschwulstforschung
|January 1, 1978
Summary
Ongoing adjuvant cancer studies are reviewed, highlighting the need for more data on immunotherapeutic agents. Defining optimal drug selection, dosing, and treatment duration is crucial for improving surgical adjuvant chemotherapy benefits.
Area of Science:
- Oncology
- Cancer Research
- Immunotherapy
Background:
- Review of ongoing National Cancer Institute-sponsored adjuvant studies.
- Identifies current gaps in knowledge regarding immunotherapeutic agents.
- Highlights the establishment of foundational principles for selecting adjuvant therapies.
Purpose of the Study:
- To illustrate new concepts and treatments in adjuvant cancer studies.
- To emphasize the need for more data to rationalize the use of immunotherapeutic agents.
- To outline strategies for enhancing the benefits of surgical adjuvant chemotherapy.
Main Methods:
- Review of ongoing National Cancer Institute-sponsored clinical trials.
- Analysis of current knowledge on immunotherapeutic agents and chemotherapy.
- Identification of areas requiring further definition in adjuvant treatment protocols.
Main Results:
- Foundational principles for selecting adjuvant drugs and combinations are emerging.
- Key areas requiring further definition include dose, schedule, and duration of treatment.
- Progress in immunotherapy and chemotherapy is expected to expand the scope of adjuvant studies.
Conclusions:
- Further research is needed to optimize immunotherapeutic agent use in adjuvant settings.
- Defining treatment parameters is essential for maximizing the efficacy of adjuvant chemotherapy.
- Advancements in treatment modalities will likely broaden the applicability of adjuvant studies across more tumor types.